Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2008;39:1575-1582
Published online before print March 6, 2008, doi: 10.1161/STROKEAHA.107.501486
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
39/5/1575    most recent
STROKEAHA.107.501486v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gee, J. M.
Right arrow Articles by Becker, K. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gee, J. M.
Right arrow Articles by Becker, K. J.
Related Collections
Right arrow Animal models of human disease
Right arrow Other Stroke Treatment - Medical

(Stroke. 2008;39:1575.)
© 2008 American Heart Association, Inc.


Original Contributions

Induction of Immunologic Tolerance to Myelin Basic Protein Prevents Central Nervous System Autoimmunity and Improves Outcome After Stroke

J. Michael Gee, BS; Angela Kalil, BA; Matthew Thullbery, MS Kyra J. Becker, MD

From Department of Neurology, University of Washington School of Medicine, Harborview Medical Center, Seattle, Wash.

Correspondence to Kyra J. Becker, MD, Box 359775 HMC, 325 9th Ave, Seattle, WA 98104-2499. E-mail kjb{at}u.washington.edu

Background and Purpose— Animals subjected to an inflammatory insult at the time of stroke are predisposed to the development of an inflammatory autoimmune response to brain. This response is associated with worse neurological outcome. Because induction of immunologic tolerance to brain antigens before stroke onset is associated with improved outcome, we sought to determine whether this paradigm could prevent the deleterious autoimmune response to brain provoked by an inflammatory stimulus at the time of ischemia.

Methods— Male Lewis rats were tolerized to myelin basic protein (MBP) or ovalbumin by intranasal administration before middle cerebral artery occlusion. At the time of reperfusion, all animals received lipopolysaccharide (1 mg/kg intraperitoneal). Behavioral tests were performed at set time intervals.

Results— One month after middle cerebral artery occlusion, lymphocytes from the spleens of MBP-tolerized animals were less likely to evidence an autoimmune response and more likely to evidence a regulatory response (TREG) toward MBP than those from ovalbumin-tolerized animals. Animals that had an inflammatory response toward MBP (a TH1 response) performed worse on behavioral tests than those that did not. Fractalkine, a surrogate marker of inflammation, was elevated in animals with a TH1 response to MBP.

Conclusions— These data extend our previous findings and suggest that deleterious autoimmunity to brain antigens can be prevented by prophylactically inducing regulatory T-cell responses to those antigens.


Key Words: autoimmunity • mucosal tolerance • myelin basic protein • stroke • TH1 • TREG




This article has been cited by other articles:


Home page
StrokeHome page
S. Subramanian, B. Zhang, Y. Kosaka, G. G. Burrows, M. R. Grafe, A. A. Vandenbark, P. D. Hurn, and H. Offner
Recombinant T Cell Receptor Ligand Treats Experimental Stroke
Stroke, July 1, 2009; 40(7): 2539 - 2545.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
M. Gelderblom, F. Leypoldt, K. Steinbach, D. Behrens, C.-U. Choe, D. A. Siler, T. V. Arumugam, E. Orthey, C. Gerloff, E. Tolosa, et al.
Temporal and Spatial Dynamics of Cerebral Immune Cell Accumulation in Stroke
Stroke, May 1, 2009; 40(5): 1849 - 1857.
[Abstract] [Full Text] [PDF]